Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial

Meghan Karuturi, Anas Younes, Luis Fayad, Larry Kwak, Barbara Pro, Jatin Shah, Yasuhiro Oki, Rinata Simien, Mary Joy Liboon, Toni Hutto, Lei Feng, Sandra Horowitz, Yago Nieto, Paolo Anderlini, Amin Alousi, Uday Popat, L. Jeffrey Medeiros, Roberto Miranda, Michelle Fanale*

*Corresponding author for this work

Research output: Contribution to journalLetter

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)445-447
Number of pages3
JournalLeukemia and Lymphoma
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Karuturi, M., Younes, A., Fayad, L., Kwak, L., Pro, B., Shah, J., Oki, Y., Simien, R., Liboon, M. J., Hutto, T., Feng, L., Horowitz, S., Nieto, Y., Anderlini, P., Alousi, A., Popat, U., Medeiros, L. J., Miranda, R., & Fanale, M. (2016). Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: Results of a randomized phase II trial. Leukemia and Lymphoma, 57(2), 445-447. https://doi.org/10.3109/10428194.2015.1032966